FOR RESEARCH USE ONLY
Early human researchMetabolic research

MOTS-c

Mitochondrial-derived peptide researched for metabolic health, insulin sensitivity and exercise capacity.

01AMPK02Mitochondrial signalling03Insulin sensitivity
Molecular signature / mots-c
Structural identity

16-amino-acid mitochondrial-derived signalling sequence

Also known as

Mitochondrial open-reading-frame of the 12S rRNA-c · Mitochondrial-derived peptide

Research-use context

In-vitro and laboratory information only. No human-use recommendation.

Guide contentsOpen in calculator
Section 01

Compound briefing

MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene — one of a small class of mitochondrial-derived peptides (MDPs) that act as systemic metabolic signalling molecules. Endogenous MOTS-c declines with age and is correlated with insulin resistance, declining exercise capacity and metabolic dysfunction.

The research question

MOTS-c links mitochondrial signalling with whole-cell energy regulation. Its study spans AMPK activation, glucose handling and stress-responsive gene expression, making metabolic state and exercise stimulus important experimental variables.

Section 02

Mechanism & research themes

Activates AMPK, the master cellular energy-sensing pathway, driving glucose uptake, fatty-acid oxidation and mitochondrial biogenesis. Translocates to the nucleus under metabolic stress to modulate stress-response gene expression.

01

Improved insulin sensitivity in metabolic-syndrome animal models

02

Enhanced glucose homeostasis and lipid metabolism

03

Increased mitochondrial biogenesis and exercise capacity

04

Reduced adipose accumulation under high-fat-diet challenge

05

Cellular stress-resistance and longevity signals in preclinical work

06

Endogenous decline with age — replacement rationale in geroscience research

These are research themes reported across the literature, not established benefits or indications.

Section 03

Evidence assessment

Early human research

Cell and animal mechanisms are comparatively well developed, while controlled human outcome data are still emerging. Endogenous associations do not establish the effects of external administration.

What to look for

Controlled design, a defined preparation, clinically relevant endpoints and independent replication carry more weight than a single mechanism study.

What not to assume

A plausible pathway does not establish efficacy. Results across different routes, formulations and populations are not automatically interchangeable.

Section 04

Protocol literature

Commonly referenced research protocols use 5–10mg subcutaneously 2–3× weekly, often timed pre-workout. Cycles typically run 4–8 weeks on / 4 weeks off.

Reported persistence

Plasma half-life is short (approximately 1–2 hours), but downstream AMPK-mediated effects persist over days.

Calculator starting point

10 mg per reference dose

3 doses per week · 4-week cycle

1 mL default reconstitution volume

5–10 mg SC, 2–3×/week, 4–6 week cycles.

Calculator defaults are editable mathematical reference values, not dosing advice. Verify all calculations independently.

Calculate MOTS-c
Section 05

Laboratory handling

Reconstitution reference

Reconstitute a 10mg vial with 1–2mL bacteriostatic water for a 5–10mg/mL working concentration. Swirl gently.

Storage reference

Lyophilised: 2–8°C, stable 18–24 months; -20°C for long-term. Reconstituted: 2–8°C, protect from light, use within 28 days.

Minimum documentation standard

  • Record the lot identifier and review its matching analytical documentation.
  • Use aseptic technique and record diluent, final volume and calculated concentration.
  • Label preparation date, storage conditions and any light or freeze–thaw restrictions.
  • Inspect before each use and investigate unexpected colour, clarity or particulate changes.
Section 06

Limitations & safety

L1

Human clinical data remains limited; most evidence is animal and in-vitro.

L2

Transient injection-site reactions possible.

L3

Effects on hypoglycaemia risk when stacked with insulin-sensitising agents are not well characterised.

Research use only

This field note is an educational literature summary, not medical advice or a recommendation for human use. Safety statements are limited by the quality and duration of the available evidence.

Continue reading

Related field notes

Back to all field notes

Welcome to HV Labs

Please confirm your age to continue.

For research use only